Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease

Frontiers in Cellular Neuroscience

Volumn 9, Issue MAR, 2015, Pages

  Canobbio, Ilaria ^a   Abubaker, Aisha Alsheikh ^a,b   Visconte, Caterina ^a   Torti, Mauro ^a   Pula, Giordano ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b University of Bath   (United Kingdom)

Author keywords

Alzheimer s disease; Amyloid peptides; Cerebrovascular disease; Platelets; Vascular cells

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMYLOID BETA PROTEIN; ANTITHROMBOCYTIC AGENT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SECRETASE;

ALZHEIMER DISEASE; ARTICLE; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CALCIUM HOMEOSTASIS; CEREBROVASCULAR DISEASE; DISEASE COURSE; ENZYME ACTIVITY; HUMAN; NERVE DEGENERATION; NONHUMAN; ONSET AGE; OXIDATION REDUCTION POTENTIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; VASCULAR DISEASE; VASCULITIS;

EID: 84925061509     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2015.00065     Document Type: Article

References (200)

1. AD2000 Collaborative Group, Bentham, P., Gray, R., Sellwood, E., Hills, R., Crome, P., et al. (2008). Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol. 7, 41-49. doi: 10.1016/s1474-4422(07)70293-4.
2. ADAPT Research Group, Lyketsos, C. G., Breitner, J. C., Green, R. C., Martin, B. K., Meinert, C., et al. (2007). Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68, 1800-1808. doi: 10.1212/01.wnl.0000260269.93245.d2.
3. Adolfsson, R., Gottfries, C. G., Oreland, L., Wiberg, A., and Winblad, B. (1980). Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci. 27, 1029-1034. doi: 10.1016/0024-3205(80)90025-9.
4. Ahn, H. J., Zamolodchikov, D., Cortes-Canteli, M., Norris, E. H., Glickman, J. F., and Strickland, S. (2010). Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc. Natl. Acad. Sci. U S A 107, 21812-21817. doi: 10.1073/pnas.1010373107.
5. Ahtiluoto, S., Polvikoski, T., Peltonen, M., Solomon, A., Tuomilehto, J., and Winblad, B. (2010). Diabetes, Alzheimer disease and vascular dementia: a population-based neuropathologic study. Neurology 75, 1195-1202. doi: 10.1212/WNL.0b013e3181f4d7f8.
6. Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., and Thomas, R. G. (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology 54, 588-593. doi: 10.1212/WNL.54.3.588.
7. Akiyama, H., Ikeda, K., Kondo, H., and McGeer, P. L. (1992). Thrombin accumulation in brains of patients with Alzheimer's disease. Neurosci. Lett. 146, 152-154. doi: 10.1016/0304-3940(92)90065-f.
8. 2 activation in astrocytes and cerebral endothelial cells. Neuroscience 199, 375-385. doi: 10.1016/j.neuroscience.2011.09.038.
9. Bailey, T. L., Rivara, C. B., Rocher, A. B., and Hof, P. R. (2004). The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol. Res. 26, 573-578. doi: 10.1179/016164104225016272.
10. Beckman, J. S., and Koppenol, W. H. (1996). Nitric oxide, superoxide and peroxynitrite: the good, the bad and ugly.Am. J. Physiol. 271, C1424-C1437.
11. Beher, D., Hesse, L., Masters, C. L., and Multhaup, G. (1996). Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I. J. Biol. Chem. 271, 1613-1620. doi: 10.1074/jbc.271.3.1613.
12. Bell, R. D., and Zlokovic, B. V. (2009). Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118, 103-113. doi: 10.1007/s00401-009-0522-3.
13. Berridge, M. J. (2013). Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia. Prion 7, 2-13. doi: 10.4161/pri.21767.
14. Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., and Hampel, H. (2015). Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement. 11, 58-69. doi: 10.1016/j.jalz.2014.02.004.
15. Bloom, G. S. (2014). Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 71, 505-508. doi: 10.1001/jamaneurol.2013.5847.
16. Bongioanni, P., Gemignani, F., Boccardi, B., Borgna, M., and Rossi, B. (1997). Platelet monoamine oxidase molecular activity in demented patients. Ital. J. Neurol. Sci. 18, 151-156. doi: 10.1007/bf02048483.
17. Borroni, B., Agosti, C., Marcello, E., Di Luca, M., and Padovani, A. (2010). Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp. Gerontol. 45, 53-56. doi: 10.1016/j.exger.2009.08.004.
18. Borroni, B., Akkawi, N., Martini, G., Colciaghi, F., Prometti, P., Rozzini, L., et al. (2002a). Microvascular damage and platelet abnormalities in early Alzheimer's disease. J. Neurol. Sci. 203-204, 189-193. doi: 10.1016/s0022-510x(02)00289-7.
19. Borroni, B., Perani, D., Broli, M., Colciaghi, F., Garibotto, V., Paghera, B. C., et al. (2005). Pre-clinical diagnosis of Alzheimer disease combining platelet amyloid precursor protein ratio and rCBF spect analysis. J. Neurol. 252, 1359-1362. doi: 10.1007/s00415-005-0867-z.
20. Borroni, B., Volpi, R., Martini, G., Del Bono, R., Archetti, S., Colciaghi, F., et al. (2002b). Peripheral blood abnormalities in Alzheimer disease: evidence for early endothelial dysfunction. Alzheimer Dis. Assoc. Disord. 16, 150-155. doi: 10.1097/00002093-200207000-00004.
21. Bosetti, F., Brizzi, F., Barogi, S., Mancuso, M., Siciliano, G., Tendi, E. A., et al. (2002). Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease.Neurobiol. Aging 23, 371-376. doi: 10.1016/s0197-4580(01)00314-1.
22. Breen, K. C., Bruce, M., and Anderton, B. H. (1991). Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. J. Neurosci. Res. 28, 90-100. doi: 10.1002/jnr.490280109.
23. Broe, G. A., Grayson, D. A., Creasey, H. M., Waite, L. M., Casey, B. J., Bennett, H. P., et al. (2000). Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch. Neurol. 57, 1586-1591. doi: 10.1001/archneur.57.11.1586.
24. Brown, W. R., and Thore, C. R. (2011). Review: cerebral microvascular pathology in ageing and neurodegeneration.Neuropathol. Appl. Neurobiol. 37, 56-74. doi: 10.1111/j.1365-2990.2010.01139.x.
25. Brundel, M., Heringa, S. M., de Bresser, J., Koek, H. L., Zwanenburg, J. J., Jaap Kappelle, L., et al. (2012). High prevalence of cerebral microbleeds at 7Tesla MRI in patients with early Alzheimer's disease. J. Alzheimers Dis. 31, 259-263. doi: 10.3233/JAD-2012-120364.
26. Buxbaum, J. D., Thinakaran, G., Koliatsos, V., O’Callahan, J., Slunt, H. H., Price, D. L., et al. (1998). Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J. Neurosci. 18, 9629-9637.
27. Cai, H., Griendling, K. K., and Harrison, D. G. (2003). The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 24, 471-478. doi: 10.1016/s0165-6147(03)00233-5.
28. Canobbio, I., Catricalà, S., Balduini, C., and Torti, M. (2011). Calmodulin regulates the non-amyloidogenic metabolism of amyloid precursor protein in platelets. Biochim. Biophys. Acta 1813, 500-506. doi: 10.1016/j.bbamcr.2010.12.002.
29. Canobbio, I., Catricalà, S., Di Pasqua, L. G., Guidetti, G., Consonni, A., Manganaro, D., et al. (2013). Immobilized amyloid Aβ peptides support platelet adhesion and activation. FEBS Lett. 587, 2606-2611. doi: 10.1016/j.febslet.2013.06.041.
30. Canobbio, I., Guidetti, G. F., Oliviero, B., Manganaro, D., Vara, D., Torti, M., et al. (2014). Amyloid β-peptide-dependent activation of human platelets: essential role for Ca2+ and ADP in aggregation and thrombus formation.Biochem. J. 462, 513-523. doi: 10.1042/BJ20140307.
31. Cardoso, S. M., Proença, M. T., Santos, S., Santana, I., and Oliveira, C. R. (2004). Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging 25, 105-110. doi: 10.1016/s0197-4580(03)00033-2.
32. Carvalho, C., Correia, S. C., Santos, R. X., Cardoso, S., Moreira, P. I., Clark, T. A., et al. (2009). Role of mitochondrial-mediated signaling pathways in Alzheimer disease and hypoxia. J. Bioenerg. Biomembr. 41, 433-440. doi: 10.1007/s10863-009-9247-1.
33. Casserly, I. P., and Topol, E. J. (2004). Convergence of atherosclerosis and alzheimer's disease: cholesterol, inflammation and misfolded proteins. Discov. Med. 4, 149-156.
34. Catricalà, S., Torti, M., and Ricevuti, G. (2012). Alzheimer disease and platelets: how's that relevant. Immun. Ageing 9:20. doi: 10.1186/1742-4933-9-20.
35. Chi, N. F., Chien, L. N., Ku, H. L., Hu, C. J., and Chiou, H. Y. (2013). Alzheimer disease and risk of stroke: a population-based cohort study. Neurology 80, 705-711. doi: 10.1212/WNL.0b013e31828250af.
36. Christov, A., Ottman, J., Hamdheydari, L., and Grammas, P. (2008). Structural changes in Alzheimer's disease brain microvessels. Curr. Alzheimer Res. 5, 392-395. doi: 10.2174/156720508785132334.
37. Colciaghi, F., Borroni, B., Pastorino, L., Marcello, E., Zimmermann, M., Cattabeni, F., et al. (2002). [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol. Med.8, 67-74.
38. Colciaghi, F., Marcello, E., Borroni, B., Zimmermann, M., Caltagirone, C., Cattabeni, F., et al. (2004). Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62, 498-501. doi: 10.1212/01.wnl.0000106953.49802.9c.
39. Cortes-Canteli, M., Paul, J., Norris, E. H., Bronstein, R., Ahn, H. J., Zamolodchikov, D., et al. (2010). Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease.Neuron 66, 695-709. doi: 10.1016/j.neuron.2010.05.014.
40. Dale, G. L. (2005). Coated-platelets: an emerging component of the procoagulant response. J. Thromb. Haemost. 3, 2185-2192. doi: 10.1111/j.1538-7836.2005.01274.x.
41. Davies, T. A., Long, H. J., Eisenhauer, P. B., Hastey, R., Cribbs, D. H., Fine, R. E., et al. (2000). Beta amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood brain barrier endothelial cell model system. Amyloid 7, 153-165. doi: 10.3109/13506120009146830.
42. Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., et al. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913. doi: 10.1038/nm890.
43. Deane, R., Wu, Z., and Zlokovic, B. V. (2004). RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-2631. doi: 10.1161/01.str.0000143452.85382.d1.
44. De Bock, M., Wang, N., Decrock, E., Bol, M., Gadicherla, A. K., Culot, M., et al. (2013). Endothelial calcium dynamics, connexin channels and blood-brain barrier function. Prog. Neurobiol. 108, 1-20. doi: 10.1016/j.pneurobio.2013.06.001.
45. DeFronzo, R. A., and Ferrannini, E. (1991). Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14, 173-194. doi: 10.2337/diacare.14.3.173.
46. de la Torre, J. C. (2000). Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol. Aging 21, 331-342. doi: 10.1016/s0197-4580(00)00111-1.
47. de la Torre, J. C. (2004a). Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol. Res.26, 517-524. doi: 10.1179/016164104225016254.
48. de la Torre, J. C. (2004b). Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3, 184-190. doi: 10.1016/S1474-4422(04)00683-0.
49. de la Torre, J. C. (2010). Vascular risk factor detection and control may prevent Alzheimer's disease. Ageing Res. Rev. 9, 218-225. doi: 10.1016/j.arr.2010.04.002.
50. de la Torre, J. C., and Mussivand, T. (1993). Can disturbed brain microcirculation cause Alzheimer's disease?Neurol. Res. 15, 146-153.
51. Demuro, A., Mina, E., Kayed, R., Milton, S. C., Parker, I., and Glabe, C. G. (2005). Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 280, 17294-17300. doi: 10.1074/jbc.m500997200.
52. Di Luca, M., Colciaghi, F., Pastorino, L., Borroni, B., Padovani, A., and Cattabeni, F. (2000). Platelets as a peripheral district where to study pathogenetic mechanisms of alzheimer disease: the case of amyloid precursor protein. Eur. J. Pharmacol. 405, 277-283. doi: 10.1016/s0014-2999(00)00559-8.
53. Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., et al. (1990). Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 1122-1124. doi: 10.1126/science.2111583.
54. Evin, G., Zhu, A., Holsinger, R. M., Masters, C. L., and Li, Q. X. (2003). Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J. Neurosci. Res. 74, 386-392. doi: 10.1002/jnr.10745.
55. Farkas, E., and Luiten, P. G. (2001). Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64, 575-611. doi: 10.1016/s0301-0082(00)00068-x.
56. Fonseca, A. C., Ferreiro, E., Oliveira, C. R., Cardoso, S. M., and Pereira, C. F. (2013). Activation of the endoplasmic reticulum stress response by the amyloid-beta 1-40 peptide in brain endothelial cells. Biochim. Biophys. Acta1832, 2191-2203. doi: 10.1016/j.bbadis.2013.08.007.
57. Fonseca, A. C., Moreira, P. I., Oliveira, C. R., Cardoso, S. M., Pinton, P., and Pereira, C. F. (2014). Amyloid-Beta disrupts calcium and redox homeostasis in brain endothelial cells. Mol. Neurobiol. doi: 10.1007/s12035-014-8740-7. [Epub ahead of print].
58. Freedman, J. E. (2008). Oxidative stress and platelets. Arterioscler. Thromb. Vasc. Biol. 28, s11-s16. doi: 10.1161/ATVBAHA.107.159178.
59. Galeazzi, L., Casoli, T., Giunta, S., Fattoretti, P., Gracciotti, N., Caselli, U., et al. (2000). β-amyloid fragment 25-35 induces changes in cytosolic free calcium in human platelets. Ann. N Y Acad. Sci. 903, 451-456. doi: 10.1111/j.1749-6632.2000.tb06398.x.
60. Gandy, S. (2005). The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J. Clin. Invest. 115, 1121-1129. doi: 10.1172/jci200525100.
61. Garwood, C., Faizullabhoy, A., Wharton, S. B., Ince, P. G., Heath, P. R., Shaw, P. J., et al. (2013). Calcium dysregulation in relation to Alzheimer-type pathology in the ageing brain. Neuropathol. Appl. Neurobiol. 39, 788-799. doi: 10.1111/nan.12033.
62. Ghiso, J., Rostagno, A., Gardella, J. E., Liem, L., Gorevic, P. D., and Frangione, B. (1992). A 109-amino-acid C-terminal fragment of Alzheimer's-disease amyloid precursor protein contains a sequence, -RHDS-, that promotes cell adhesion. Biochem. J. 288, 1053-1059.
63. Giri, R., Shen, Y., Stins, M., Du Yan, S., Schmidt, A. M., Stern, D., et al. (2000). Beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am. J. Physiol. Cell Physiol. 279, C1772-C1781.
64. Glabe, C. G. (2006). Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 27, 570-575. doi: 10.1016/j.neurobiolaging.2005.04.017.
65. Glenner, G. G., and Wong, C. W. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890. doi: 10.1016/s0006-291x(84)80190-4.
66. Gorelick, P. B. (2004). Risk factors for vascular dementia and Alzheimer disease. Stroke 35, 2620-2622. doi: 10.1161/01.str.0000143318.70292.47.
67. Gowert, N. S., Donner, L., Chatterjee, M., Eisele, Y. S., Towhid, S. T., Münzer, P., et al. (2014). Blood platelets in the progression of Alzheimer's disease. PLoS One 9:e90523. doi: 10.1371/journal.pone.0090523.
68. Grammas, P. (2011). Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J. Neuroinflammation 8:26. doi: 10.1186/1742-2094-8-26.
69. Grammas, P., Botchlet, T., Fugate, R., Ball, M. J., and Roher, A. E. (1995). Alzheimer disease amyloid proteins inhibit brain endothelial cell proliferation in vitro. Dementia 6, 126-130. doi: 10.1159/000106934.
70. Grammas, P., Martinez, J., Sanchez, A., Yin, X., Riley, J., Gay, D., et al. (2014). A new paradigm for the treatment of Alzheimer's disease: targeting vascular activation. J. Alzheimers Dis. 40, 619-630. doi: 10.3233/JAD-2014-132057.
71. Grammas, P., and Ovase, R. (2001). Inflammatory factors are elevated in brain microvessels in Alzheimer's disease.Neurobiol. Aging 22, 837-842. doi: 10.1016/s0197-4580(01)00276-7.
72. Grammas, P., Yamada, M., and Zlokovic, B. (2002). The cerebromicrovasculature: a key player in the pathogenesis of Alzheimer's disease. J. Alzheimers Dis. 4, 217-223.
73. Hardy, J. A., and Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185. doi: 10.1126/science.1566067.
74. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi: 10.1126/science.1072994.
75. Hayashi, S., Sato, N., Yamamoto, A., Ikegame, Y., Nakashima, S., Ogihara, T., et al. (2009). Alzheimer disease-associated peptide, amyloid beta40, inhibits vascular regeneration with induction of endothelial autophagy.Arterioscler. Thromb. Vasc. Biol. 29, 1909-1915. doi: 10.1161/ATVBAHA.109.188516.
76. Henderson, A. S., Jorm, A. F., Christensen, H., Jacomb, P. A., and Korten, A. E. (1997). Aspirin, anti-inflammatory drugs and risk of dementia. Int. J. Geriatr. Psychiatry 12, 926-930. doi: 10.1002/(sici)1099-1166(199709)12:9<926::aid-gps665>3.3.co;2-p.
77. Henry, A., Li, Q. X., Galatis, D., Hesse, L., Multhaup, G., Beyreuther, K., et al. (1998). Inhibition of platelet activation by the Alzheimer's disease amyloid precursor protein. Br. J. Haematol. 103, 402-415. doi: 10.1046/j.1365-2141.1998.01005.x.
78. Herczenik, E., Bouma, B., Korporaal, S. J., Strangi, R., Zeng, Q., Gros, P., et al. (2007). Activation of human platelets by misfolded proteins. Arterioscler. Thromb. Vasc. Biol. 27, 1657-1665. doi: 10.1161/atvbaha.107.143479.
79. Honjo, K., Black, S. E., and Verhoeff, N. P. (2012). Alzheimer's disease, cerebrovascular disease and the β-amyloid cascade. Can. J. Neurol. Sci. 39, 712-728. doi: 10.1017/s0317167100015547.
80. Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., et al. (2008). Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131, 1630-1645. doi: 10.1093/brain/awn016.
81. in 't Veld, B. A., Launer, L. J., Breteler, M. M., Hofman, A., and Stricker, B. H. (2002). Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. Epidemiol. Rev.24, 248-268. doi: 10.1093/epirev/mxf001.
82. Iwatsubo, T. (2004). The gamma-secretase complex: machinery for intramembrane proteolysis. Curr. Opin. Neurobiol. 14, 379-383. doi: 10.1016/s0959-4388(04)00077-7.
83. Jarre, A., Gowert, N. S., Donner, L., Münzer, P., Klier, M., Borst, O., et al. (2014). Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease. Cell. Signal. 26, 2040-2050. doi: 10.1016/j.cellsig.2014.05.019.
84. Jellinger, K. A. (2002). Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm. 109, 813-836. doi: 10.1007/s007020200068.
85. Jellinger, K. A. (2010). Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases.Neurodegener. Dis. 7, 112-115. doi: 10.1159/000285518.
86. Johnston, J. A., Liu, W. W., Coulson, D. T., Todd, S., Murphy, S., Brennan, S., et al. (2008). Platelet beta-secretase activity is increased in Alzheimer's disease. Neurobiol. Aging 29, 661-668. doi: 10.1016/j.neurobiolaging.2006.11.003.
87. Kalaria, R. N. (2010). Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr. Rev. 68(Suppl. 2), S74-S87. doi: 10.1111/j.1753-4887.2010.00352.x.
88. Kalaria, R. N., and Pax, A. B. (1995). Increased collagen content of cerebral microvessels in Alzheimer's disease.Brain Res. 705, 349-352. doi: 10.1016/0006-8993(95)01250-8.
89. Kaminsky, Y. G., Marlatt, M. W., Smith, M. A., and Kosenko, E. A. (2010). Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Aβ(25-35). Exp. Neurol. 221, 26-37. doi: 10.1016/j.expneurol.2009.09.005.
90. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., et al. (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736. doi: 10.1038/325733a0.
91. Kara, F., Dongen, E. S., Schliebs, R., Buchem, M. A., Groot, H. J., and Alia, A. (2012). Monitoring blood flow alterations in the Tg2576 mouse model of Alzheimer's disease by in vivo magnetic resonance angiography at 17.6 T. Neuroimage 60, 958-966. doi: 10.1016/j.neuroimage.2011.12.055.
92. Kelleher, R. J., and Soiza, R. L. (2013). Evidence of endothelial dysfunction in the development of Alzheimer's disease: is Alzheimer's a vascular disorder? Am. J. Cardiovasc. Dis. 3, 197-226.
93. Kennedy, J. L., Farrer, L. A., Andreasen, N. C., Mayeux, R., and St George-Hyslop, P. (2003). The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science 302, 822-826. doi: 10.1126/science.1092132.
94. Kitazume, S., Yoshihisa, A., Yamaki, T., Oikawa, M., Tachida, Y., Ogawa, K., et al. (2012). Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome. J. Biol. Chem. 287, 40817-40825. doi: 10.1074/jbc.M112.398578.
95. Kokjohn, T. A., Van Vickle, G. D., Maarouf, C. L., Kalback, W. M., Hunter, J. M., Daugs, I. D., et al. (2011). Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets.Biochim. Biophys. Acta 1812, 1508-1514. doi: 10.1016/j.bbadis.2011.07.004.
96. 1-42-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca2+-calcineurin signaling. J. Neurosci. 32, 8845-8854. doi: 10.1523/JNEUROSCI.6102-11.2012.
97. Kuo, Y. M., Kokjohn, T. A., Watson, M. D., Woods, A. S., Cotter, R. J., Sue, L. I., et al. (2000). Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am. J. Pathol.156, 797-805. doi: 10.1016/s0002-9440(10)64947-4.
98. Laske, C. (2012). Alzheimer disease: blood-based biomarkers in AD-a silver lining on the horizon. Nat. Rev. Neurol.8, 541-542. doi: 10.1038/nrneurol.2012.173.
99. Laske, C., Sopova, K., Gkotsis, C., Eschweiler, G. W., Straten, G., Gawaz, M., et al. (2010). Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. J. Alzheimers Dis. 21, 1263-1269.
100. Lee, H. G., Casadesus, G., Zhu, X., Joseph, J. A., Perry, G., and Smith, M. A. (2004). Perspectives on the amyloid-beta cascade hypothesis. J. Alzheimers Dis. 6, 137-145.
101. Lee, M. J., Seo, S. W., Na, D. L., Kim, C., Park, J. H., Kim, G. H., et al. (2014). Synergistic effects of ischemia and β-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment. JAMA Psychiatry 71, 412-422. doi: 10.1001/jamapsychiatry.2013.4506.
102. Leo, R., Praticò, D., Iuliano, L., Pulcinelli, F. M., Ghiselli, A., Pignatelli, P., et al. (1997). Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. Circulation 95, 885-891. doi: 10.1161/01.cir.95.4.885.
103. Li, Q. X., Berndt, M. C., Bush, A. I., Rumble, B., Mackenzie, I., and Friedhuber, A. (1994). Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood 84, 133-142.
104. Li, J. C., Han, L., Wen, Y. X., Yang, Y. X., Li, S., Li, X. S., et al. (2015). Increased permeability of the blood-brain barrier and Alzheimer's disease-like alterations in slit-2 transgenic mice. J. Alzheimers Dis. 43, 535-548. doi: 10.3233/JAD-141215.
105. Li, M., Shang, D. S., Zhao, W. D., Tian, L., Li, B., Fang, W. G., et al. (2009). Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J. Immunol. 182, 5778-5788. doi: 10.4049/jimmunol.0803013.
106. Li, Q. X., Whyte, S., Tanner, J. E., Evin, G., Beyreuther, K., and Masters, C. L. (1998). Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab. Invest. 78, 461-469.
107. Liu, W. W., Todd, S., Craig, D., Passmore, A. P., Coulson, D. T., Murphy, S., et al. (2007). Elevated platelet β-secretase activity in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 24, 464-468. doi: 10.1159/000110739.
108. Loll, P. J., Picot, D., and Garavito, R. M. (1995). The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. 2, 637-643. doi: 10.1038/nsb0895-637.
109. Lorenzo, A., Yuan, M., Zhang, Z., Paganetti, P. A., Sturchler-Pierrat, C., Staufenbiel, M., et al. (2000). Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat. Neurosci. 3, 460-464. doi: 10.1038/74833.
110. Lue, L. F., Walker, D. G., Brachova, L., Beach, T. G., Rogers, J., Schmidt, A. M., et al. (2001). Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp. Neurol. 171, 29-45. doi: 10.1006/exnr.2001.7732.
111. Menting, K. W., and Claassen, J. A. (2014). β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. Front. Aging Neurosci. 6:165. doi: 10.3389/fnagi.2014.00165.
112. Mészáros, Z., Borcsiczky, D., Máté, M., Tarcali, J., Szombathy, T., Tekes, K., et al. (1998). Platelet MAO-B activity and serotonin content in patients with dementia: effect of age, medication and disease. Neurochem. Res. 23, 863-868. doi: 10.1023/A:1022458928442.
113. Mhatre, M., Nguyen, A., Kashani, S., Pham, T., Adesina, A., and Grammas, P. (2004). Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol. Aging 25, 783-793. doi: 10.1016/s0197-4580(03)00192-1.
114. Michaelson, D. M. (2014). APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease.Alzheimers Dement. 10, 861-868. doi: 10.1016/j.jalz.2014.06.015.
115. Miller, T. W., Isenberg, J. S., Shih, H. B., Wang, Y., and Roberts, D. D. (2010). Amyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent manner. PLoS One 5:e15686. doi: 10.1371/journal.pone.0015686.
116. Milward, E. A., Papadopoulos, R., Fuller, S. J., Moir, R. D., Small, D., Beyreuther, K., et al. (1992). The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth.Neuron 9, 129-137. doi: 10.1016/0896-6273(92)90228-6.
117. Molnar, F. J., Man-Son-Hing, M., St John, P., Brymer, C., Rockwood, K., and Hachinski, V. (1998). Subcortical vascular dementia: survey of treatment patterns and research considerations. Can. J. Neurol. Sci. 25, 320-324.
118. Morris, J. K., Honea, R. A., Vidoni, E. D., Swerdlow, R. H., and Burns, J. M. (2014). Is Alzheimer's disease a systemic disease?. Biochim. Biophys. Acta 1842, 1340-1349. doi: 10.1016/j.bbadis.2014.04.012.
119. Murphy, M. P., and LeVine, H. 3rd (2010). Alzheimer's disease and the amyloid-beta peptide. J. Alzheimers Dis. 19, 311-323. doi: 10.3233/JAD-2010-1221.
120. Nakayama, K., Nagase, H., Koh, C. S., and Ohkawara, T. (2011). γ-Secretase-regulated mechanisms similar to notch signaling may play a role in signaling events, including APP signaling, which leads to Alzheimer's disease. Cell. Mol. Neurobiol. 31, 887-900. doi: 10.1007/s10571-011-9688-z.
121. Okamoto, T., Takeda, S., Murayama, Y., Ogata, E., and Nishimoto, I. (1995). Ligand-dependent G protein coupling function of amyloid transmembrane precursor. J. Biol. Chem. 270, 4205-4208. doi: 10.1074/jbc.270.9.4205.
122. Paasonen, M. K., Solatunturi, E., and Kivalo, E. (1964). Monoamine oxidase activity of blood platelets and their ability to store 5-hydroxytryptamine in some mental deficiencies. Psychopharmacologia 6, 120-124. doi: 10.1007/bf00413224.
123. Paris, D., Patel, N., DelleDonne, A., Quadros, A., Smeed, R., and Mullan, M. (2004). Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci. Lett. 366, 80-85. doi: 10.1016/j.neulet.2004.05.017.
124. Park, L., Anrather, J., Zhou, P., Frys, K., Pitstick, R., Younkin, S., et al. (2005). NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J. Neurosci. 25, 1769-1777. doi: 10.1523/jneurosci.5207-04.2005.
125. Park, K. W., and Jin, B. K. (2008). Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase. J. Neurosci. Res. 86, 1053-1063. doi: 10.1002/jnr.21571.
126. Paul, J., Strickland, S., and Melchor, J. P. (2007). Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med. 204, 1999-2008. doi: 10.1084/jem.20070304.
127. Pogue, A. I., and Lukiw, W. J. (2004). Angiogenic signaling in Alzheimer's disease. Neuroreport 15, 1507-1510. doi: 10.1097/01.wnr.0000130539.39937.1d.
128. Pollard, H. B., Rojas, E., and Arispe, N. (1993). A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid beta protein (AβP) in phospholipid bilayer membranes. Ann. N Y Acad. Sci. 695, 165-168. doi: 10.1111/j.1749-6632.1993.tb23046.x.
129. Price, J. M., Chi, X., Hellermann, G., and Sutton, E. T. (2001). Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production. Neurol. Res. 23, 506-512. doi: 10.1179/016164101101198758.
130. Prodan, C. I., Ross, E. D., Vincent, A. S., and Dale, G. L. (2007). Coated-platelets are higher in amnestic versus nonamnestic patients with mild cognitive impairment. Alzheimer Dis. Assoc. Disord. 21, 259-261. doi: 10.1097/wad.0b013e31811ec11f.
131. Prodan, C. I., Ross, E. D., Vincent, A. S., and Dale, G. L. (2008). Rate of progression in Alzheimer's disease correlates with coated-platelet levels-a longitudinal study. Transl. Res. 152, 99-102. doi: 10.1016/j.trsl.2008.07.001.
132. Prodan, C. I., Szasz, R., Vincent, A. S., Ross, E. D., and Dale, G. L. (2006). Coated-platelets retain amyloid precursor protein on their surface. Platelets 17, 56-60. doi: 10.1080/09537100500181913.
133. Prodan, C. I., Vincent, A. S., Padmanabhan, R., and Dale, G. L. (2009). Coated-platelet levels are low in patients with spontaneous intracerebral hemorrhage. Stroke 40, 2578-2580. doi: 10.1161/STROKEAHA.109.549014.
134. Purandare, N., and Burns, A. (2009). Cerebral emboli in the genesis of dementia. J. Neurol. Sci. 283, 17-20. doi: 10.1016/j.jns.2009.02.306.
135. Rao, H. V., Thirumangalakudi, L., and Grammas, P. (2009). Cyclin C and cyclin dependent kinases 1, 2 and 3 in thrombin-induced neuronal cell cycle progression and apoptosis. Neurosci. Lett. 450, 347-350. doi: 10.1016/j.neulet.2008.12.018.
136. Reznik-Wolf, H., Machado, J., Haroutunian, V., DeMarco, L., Walter, G. F., and Goldman, B. (1998). Somatic mutation analysis of the APP and Presenilin 1 and 2 genes in Alzheimer's disease brains. J. Neurogenet. 12, 55-65. doi: 10.3109/01677069809108555.
137. Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Van Vickle, G. D., Kalback, W. M., et al. (2009). Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 5, 18-29. doi: 10.1016/j.jalz.2008.10.004.
138. Roher, A. E., Esh, C., Kokjohn, T. A., Kalback, W., Luehrs, D. C., Seward, J. D., et al. (2003). Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler. Thromb. Vasc. Biol. 23, 2055-2062. doi: 10.1161/01.atv.0000095973.42032.44.
139. Rowley, J. W., Oler, A. J., Tolley, N. D., Hunter, B. N., Low, E. N., Nix, D. A., et al. (2011). Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 118, e101-e111. doi: 10.1182/blood-2011-03-339705.
140. Sakurai, H., Hanyu, H., Sato, T., Kume, K., Hirao, K., Kanetaka, H., et al. (2013). Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study.Geriatr. Gerontol. Int. 13, 90-97. doi: 10.1111/j.1447-0594.2012.00866.x.
141. Sasaki, N., Toki, S., Chowei, H., Saito, T., Nakano, N., Hayashi, Y., et al. (2001). Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res.888, 256-262. doi: 10.1016/s0006-8993(00)03075-4.
142. Scandura, J. M., Zhang, Y., Van Nostrand, W. E., and Walsh, P. N. (1997). Progress curve analysis of the kinetics with which blood coagulation factor XIa is inhibited by protease nexin-2. Biochemistry 36, 412-420. doi: 10.1021/bi9612576.
143. Scheuermann, S., Hambsch, B., Hesse, L., Stumm, J., Schmidt, C., Beher, D., et al. (2001). Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J. Biol. Chem.276, 33923-33929. doi: 10.1074/jbc.m105410200.
144. Schmaier, A. H., Dahl, L. D., Hasan, A. A., Cines, D. B., Bauer, K. A., and Van Nostrand, W. E. (1995). Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes.Biochemistry 34, 1171-1178. doi: 10.1021/bi00004a010.
145. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., et al. (1992). Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327. doi: 10.1038/359325a0.
146. Sevush, S., Jy, W., Horstman, L. L., Mao, W. W., Kolodny, L., and Ahn, Y. S. (1998). Platelet activation in Alzheimer disease. Arch. Neurol. 55, 530-536. doi: 10.1001/archneur.55.4.530.
147. Shen, M. Y., Hsiao, G., Fong, T. H., Chen, H. M., Chou, D. S., Lin, C. H., et al. (2008a). Amyloid beta peptide-activated signal pathways in human platelets. Eur. J. Pharmacol. 588, 259-266. doi: 10.1016/j.ejphar.2008.04.040.
148. Shen, M. Y., Hsiao, G., Fong, T. H., Chou, D. S., and Sheu, J. R. (2008b). Expression of amyloid beta peptide in human platelets: pivotal role of the phospholipase Cgamma2-protein kinase C pathway in platelet activation.Pharmacol. Res. 57, 151-158. doi: 10.1016/j.phrs.2008.01.004.
149. Smirnova, I. V., Zhang, S. X., Citron, B. A., Arnold, P. M., and Festoff, B. W. (1998). Thrombin is an extracellular signal that activates intracellular death protease pathways inducing apoptosis in model motor neurons. J. Neurobiol. 36, 64-80. doi: 10.1002/(sici)1097-4695(199807)36:1<64::aid-neu6>3.3.co;2-4.
150. Smith, R. P., Higuchi, D. A., and Broze, G. J. Jr. (1990). Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 248, 1126-1128. doi: 10.1126/science.2111585.
151. Smolarkiewicz, M., Skrzypczak, T., and Wojtaszek, P. (2013). The very many faces of presenilins and the γ-secretase complex. Protoplasma 250, 997-1011. doi: 10.1007/s00709-013-0494-y.
152. Sola Vigo, F., Kedikian, G., Heredia, L., Heredia, F., Añel, A. D., Rosa, A. L., et al. (2009). Amyloid-beta precursor protein mediates neuronal toxicity of amyloid beta through Go protein activation. Neurobiol. Aging 30, 1379-1392. doi: 10.1016/j.neurobiolaging.2007.11.017.
153. Sonkar, V. K., Kulkarni, P. P., and Dash, D. (2014). Amyloid β peptide stimulates platelet activation through RhoA-dependent modulation of actomyosin organization. FASEB J. 28, 1819-1829. doi: 10.1096/fj.13-243691.
154. Sorrentino, P., Iuliano, A., Polverino, A., Jacini, F., and Sorrentino, G. (2014). The dark sides of amyloid in Alzheimer's disease pathogenesis. FEBS Lett. 588, 641-652. doi: 10.1016/j.febslet.2013.12.038.
155. Stellos, K., Panagiota, V., Kögel, A., Leyhe, T., Gawaz, M., and Laske, C. (2010). Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients. J. Cereb. Blood Flow Metab. 30, 1817-1820. doi: 10.1038/jcbfm.2010.140.
156. Stewart, P. A., Hayakawa, K., Akers, M. A., and Vinters, H. V. (1992). A morphometric study of the blood-brain barrier in Alzheimer's disease. Lab. Invest. 67, 734-742.
157. Stokes, K. Y., Russell, J. M., Jennings, M. H., Alexander, J. S., and Granger, D. N. (2007). Platelet-associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia. Free Radic. Biol. Med. 43, 22-30. doi: 10.1016/j.freeradbiomed.2007.02.027.
158. Suo, Z., Wu, M., Citron, B. A., Palazzo, R. E., and Festoff, B. W. (2003). Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling. J. Biol. Chem. 278, 37681-37689. doi: 10.1074/jbc.m301406200.
159. Sutcliffe, J. G., Hedlund, P. B., Thomas, E. A., Bloom, F. E., and Hilbush, B. S. (2011). Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease. J. Neurosci. Res. 89, 808-814. doi: 10.1002/jnr.22603.
160. Szekely, C. A., and Zandi, P. P. (2010). Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol. Disord. Drug Targets. 9, 132-139. doi: 10.2174/187152710791012026.
161. Takuma, K., Fang, F., Zhang, W., Yan, S., Fukuzaki, E., Du, H., et al. (2009). RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc. Natl. Acad. Sci. U S A 106, 20021-20026. doi: 10.1073/pnas.0905686106.
162. Tang, K., Hynan, L. S., Baskin, F., and Rosenberg, R. N. (2006). Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J. Neurol. Sci. 240, 53-58. doi: 10.1016/j.jns.2005.09.002.
163. Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., et al. (2005). A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30, 1204-1215. doi: 10.1038/sj.npp.1300690.
164. Thal, D. R., Ghebremedhin, E., Orantes, M., and Wiestler, O. D. (2003). Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J. Neuropathol. Exp. Neurol. 62, 1287-1301.
165. The Lancet Neurology. (2010). How much is dementia care worth? Lancet Neurol. 9:1037. doi: 10.1016/S1474-4422(10)70257-X.
166. Thirumangalakudi, L., Samany, P. G., Owoso, A., Wiskar, B., and Grammas, P. (2006). Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. J. Alzheimers Dis. 10, 111-118.
167. Tibolla, G., Norata, G. D., Meda, C., Arnaboldi, L., Uboldi, P., Piazza, F., et al. (2010). Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. Atherosclerosis 210, 78-87. doi: 10.1016/j.atherosclerosis.2009.10.040.
168. Tjernberg, L. O., Callaway, D. J., Tjernberg, A., Hahne, S., Lilliehöök, C., Terenius, L., et al. (1999). A molecular model of Alzheimer amyloid beta-peptide fibril formation. J. Biol. Chem. 274, 12619-12625. doi: 10.1074/jbc.274.18.12619.
169. Tolppanen, A. M., Lavikainen, P., Solomon, A., Kivipelto, M., Soininen, H., and Hartikainen, S. (2013). Incidence of stroke in people with Alzheimer disease: a national register-based approach. Neurology 80, 353-358. doi: 10.1212/WNL.0b013e31827f08c5.
170. Tripathy, D., Sanchez, A., Yin, X., Luo, J., Martinez, J., and Grammas, P. (2013). Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. Front. Aging Neurosci. 5:19. doi: 10.3389/fnagi.2013.00019.
171. Truran, S., Franco, D. A., Roher, A. E., Beach, T. G., Burciu, C., Serrano, G., et al. (2014). Adipose and leptomeningeal arteriole endothelial dysfunction induced by β-amyloid peptide: a practical human model to study Alzheimer's disease vasculopathy. J. Neurosci. Methods 235, 123-129. doi: 10.1016/j.jneumeth.2014.06.014.
172. Tsopanoglou, N. E., Andriopoulou, P., and Maragoudakis, M. E. (2002). On the mechanism of thrombin-induced angiogenesis: involvement of alphavbeta3-integrin. Am. J. Physiol. Cell Physiol. 283, C1501-C1510. doi: 10.1152/ajpcell.00162.2002.
173. Van Nostrand, W. E., and Melchor, J. P. (2001). Disruption of pathologic amyloid beta-protein fibril assembly on the surface of cultured human cerebrovascular smooth muscle cells. Amyloid 8(Suppl. 1), 20-27.
174. Van Nostrand, W. E., Melchor, J. P., Keane, D. M., Saporito-Irwin, S. M., Romanov, G., Davis, J., et al. (2002). Localization of a fibrillar amyloid beta-protein binding domain on its precursor. J. Biol. Chem. 277, 36392-36398. doi: 10.1074/jbc.m204676200.
175. Van Nostrand, W. E., Schmaier, A. H., Farrow, J. S., and Cunningham, D. D. (1990). Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. Science 248, 745-748. doi: 10.1126/science.2110384.
176. Van Nostrand, W. E., Schmaier, A. H., Neiditch, B. R., Siegel, R. S., Raschke, W. C., Sisodia, S. S., et al. (1994). Expression, purification and characterization of the Kunitz-type proteinase inhibitor domain of the amyloid beta-protein precursor-like protein-2. Biochim. Biophys. Acta 1209, 165-170. doi: 10.1016/0167-4838(94)90180-5.
177. Van Nostrand, W. E., Schmaier, A. H., and Wagner, S. L. (1992). Potential role of protease nexin-2/amyloid beta-protein precursor as a cerebral anticoagulant. Ann. N Y Acad. Sci. 674, 243-252. doi: 10.1111/j.1749-6632.1992.tb27493.x.
178. Van Nostrand, W. E., Wagner, S. L., Suzuki, M., Choi, B. H., Farrow, J. S., and Geddes, J. W. (1989). Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature 341, 546-549. doi: 10.1038/341546a0.
179. Vara, D., Campanella, M., and Pula, G. (2013). The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner. Br. J. Pharmacol. 168, 212-224. doi: 10.1111/j.1476-5381.2012.02130.x.
180. Vassar, R., Kuhn, P. H., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., et al. (2014). Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J. Neurochem. 130, 4-28. doi: 10.1111/jnc.12715.
181. Veitinger, M., Varga, B., Guterres, S. B., and Zellner, M. (2014). Platelets, a reliable source for peripheral Alzheimer's disease biomarkers? Acta Neuropathol. Commun. 2:65. doi: 10.1186/2051-5960-2-65.
182. Verdier, Y., and Penke, B. (2004). Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. Curr. Protein Pept. Sci. 5, 19-31. doi: 10.2174/1389203043486937.
183. Vingtdeux, V., and Marambaud, P. (2012). Identification and biology of α-secretase. J. Neurochem. 120(Suppl. 1), 34-45. doi: 10.1111/j.1471-4159.2011.07477.x.
184. Viswanathan, A., and Greenberg, S. M. (2011). Cerebral amyloid angiopathy in the elderly. Ann. Neurol. 70, 871-880. doi: 10.1002/ana.22516.
185. Viswanathan, A., Rocca, W. A., and Tzourio, C. (2009). Vascular risk factors and dementia: how to move forward?Neurology 72, 368-374. doi: 10.1212/01.wnl.0000341271.90478.8e.
186. Vukic, V., Callaghan, D., Walker, D., Lue, L. F., Liu, Q. Y., Couraud, P. O., et al. (2009). Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol. Dis. 34, 95-106. doi: 10.1016/j.nbd.2008.12.007.
187. Wautier, M. P., Chappey, O., Corda, S., Stern, D. M., Schmidt, A. M., and Wautier, J. L. (2001). Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280, E685-E694.
188. Wilkerson, W. R., and Sane, D. C. (2002). Aging and thrombosis. Semin. Thromb. Hemost. 28, 555-568. doi: 10.1055/s-2002-36700.
189. Williamson, T. G., Mok, S. S., Henry, A., Cappai, R., Lander, A. D., Nurcombe, V., et al. (1996). Secreted glypican binds to the amyloid precursor protein of Alzheimer's disease (APP) and inhibits APP-induced neurite outgrowth.J. Biol. Chem. 271, 31215-31221. doi: 10.1074/jbc.271.49.31215.
190. World Alzheimer Report. (2011). The Benefits of Early Diagnosis and Intervention. London, UK: Alzheimer's disease International. Available online at: http://www.alz.co.uk/research/world-report-2011.
191. Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R. D., Deane, R., et al. (2005). Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 11, 959-965.
192. Xu, F., Davis, J., Miao, J., Previti, M. L., Romanov, G., Ziegler, K., et al. (2005). Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. Proc. Natl. Acad. Sci. U S A 102, 18135-18140. doi: 10.1073/pnas.0507798102.
193. Xu, F., Kotarba, A. E., Ou-Yang, M. H., Fu, Z., Davis, J., Smith, S. O., et al. (2014). Early-onset formation of parenchymal plaque amyloid abrogates cerebral microvascular amyloid accumulation in transgenic mice. J. Biol. Chem. 289, 17895-17908. doi: 10.1074/jbc.M113.536565.
194. Xu, F., Previti, M. L., and Van Nostrand, W. E. (2007). Increased severity of hemorrhage in transgenic mice expressing cerebral protease nexin-2/amyloid beta-protein precursor. Stroke 38, 2598-2601. doi: 10.1161/strokeaha.106.480103.
195. Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., et al. (1996). RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691. doi: 10.1038/382685a0.
196. Yeung, J., and Holinstat, M. (2012). Newer agents in antiplatelet therapy: a review. J. Blood Med. 3, 33-42. doi: 10.2147/JBM.S25421.
197. Yin, X., Wright, J., Wall, T., and Grammas, P. (2010). Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. Am. J. Pathol. 176, 1600-1606. doi: 10.2353/ajpath.2010.090406.
198. Zhang, W., Huang, W., and Jing, F. (2013). Contribution of blood platelets to vascular pathology in Alzheimer's disease. J. Blood Med. 4, 141-147. doi: 10.2147/JBM.S45071.
199. Zlokovic, B. V. (2005). Neurovascular mechanisms of Alzheimer's neuro-degeneration. Trends Neurosci. 28, 202-208. doi: 10.1016/j.tins.2005.02.001.
200. Zuliani, G., Cavalieri, M., Galvani, M., Passaro, A., Munari, M. R., Bosi, C., et al. (2008). Markers of endothelial dysfunction in older subjects with late onset alzheimer's disease or vascular dementia. J. Neurol. Sci. 272, 164-170. doi: 10.1016/j.jns.2008.05.020.